

Welcome to California Department of Public Health California COVID-19 Vaccination Program Friday Provider Office Hours



Vaccinate ALL 58
Together we can end the pandemic.

Friday, March 11, 2022

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
<https://eziz.org/covid/education/>



For assistance, please contact Rachel.Jacobs@cdph.ca.gov

Agenda: Friday, March 11, 2022

No.	Item	Speaker	Time (AM)
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 – 9:05
2	Vaccine Administration	Elizabeth Reosti (CDPH)	9:05 – 9:10
3	COVID-19 Quality Assurance Site Visits	Steven Vantine and Kelsey Florio (CDPH)	9:10 – 9:15
4	Clinical Update	Caterina Liu, M.D. (CDPH)	9:15 – 9:20
Q&A			9:20 – 9:30
5	Storage & Handling	Kate McHugh (CDPH)	9:30 – 9:35
6	Vaccine Management	Eric Norton (My Turn) and Claudia Aguiluz (CDPH)	9:35 – 9:45
7	Wrap Up & Resources	Leslie Amani (Moderator)	9:45 – 10:00
Q&A			

Announcements

Leslie Amani, CDPH



My Turn Screening Questions: 16 Languages

- Arabic
- Armenian
- Dari
- English
- Farsi
- Japanese
- Khmer
- Korean
- Pashto
- Punjabi
- Russian
- Simplified Chinese
- Spanish
- Tagalog
- Traditional Chinese
- Vietnamese

Arabic

My Turn

تأكيد العمر

☐ أقر أنني، الشخص الذي يقدم معلومات المريض، أبلغ من العمر 18 عامًا على الأقل، أو متحرراً قاصراً لا يقل عمره عن 16 عامًا، أو والد المريض القاصر.

أسئلة الفحص الطبي

هل تشعر بالمرض اليوم؟

هل سبق أن تلقيت جرعة من لقاح كوفيد-19؟

هل سبق أن عانيت من حساسية تجاه (1) مكرن من لقاح كوفيد-19، بما في ذلك البروتين الليفيين جلايكول (PEG) الموجود في بعض الأدوية، مثل الأنوية المسببة والمثلية والمستحضرات المستخدمة في إجراءات تنظيم القترن، (2) والبولي سوريات، (3) وجرعة سابقة من لقاح كوفيد-19؟ (قد يشمل ذلك حساسية شديدة (على سبيل المثال، التقيؤ، القيء، أي الحساسية المفرطة) تطلبت علاجاً باستخدام الأبينفرين أو EpiPen® أو تسببت في ذهابك إلى المستشفى. وقد يشمل أيضاً حساسية حدثت في غضون 4 ساعات وتسببت في مرض الشرى أو التورم أو ضائقة تنفسية، بما في ذلك الصغير.)

هل سبق أن عانيت من حساسية تجاه لقاح آخر (بخلاف لقاح كوفيد-19) أو تجاه أي دواء يُمنح عن طريق الحقن؟ (قد يشمل ذلك حساسية شديدة (على سبيل المثال، التقيؤ، القيء، أي الحساسية المفرطة) تطلبت علاجاً باستخدام الأبينفرين أو EpiPen® أو تسببت في ذهابك إلى المستشفى. وقد يشمل أيضاً حساسية حدثت في غضون 4 ساعات وتسببت في مرض الشرى أو التورم أو ضائقة تنفسية، بما في ذلك الصغير.)

هل عانيت قبل ذلك من رد فعل تحسسي شديد (مثل الحساسية المفرطة) لتسليح آخر غير أحد مكونات لقاح كوفيد-19 أو الوبليوسيرات أو أي لقاح أو دواء يُعطى عن طريق الحقن؟ قد يشمل ذلك الحساسية من الطعام أو الحيوانات الأليفة أو البيئة أو الأدوية التي تؤخذ عن طريق الفم.

هل سبق وتخصصت بمعالجة التهاب الأجهزة المتعددة (MIS-C أو MIS-A) بعد الإصابة بكوفيد-19؟

هل تلقيت علاجاً سلبياً بالأجسام المضادة (الأجسام المضادة وحيدة النسيلة أو مصل الدقيقين) كعلاج لكوفيد-19؟

هل جهازك المناعي ضعيف بسبب مرض مثل فيروس نقص المناعة البشرية أو السرطان، أو هل تتناول أدوية أو علاجات مثبطة للمناعة؟

هل تعاني اضطراب القلق أو تتناول مميعات الدم؟

هل سبق وعانيت من قلة الصفائح الدموية التي يسببها الهيبارين (HIT)؟

هل أنت حامل أو ترضعن رضاعة طبيعية؟

هل تلقيت حقنات جلدية؟

هل سبق وعانيت من التهاب عضلة القلب أو التهاب غلاف القلب (التهامور)؟

هل أصيب المريض بمتلازمة غيلان باريه (GBS) من قبل؟

منذ تلقيك CAR-T أو علاجات خلايا (HCT) هل خضعت لرعاية الخلايا المكونة للدم للقاح كوفيد-19؟

COVID screening questions and consent - translations



#CrucialCOVIDConversations on Social Media

CDPH needs your help on social media to guide the public, answer questions, and fight back against the latest misinformation.

We are encouraging all healthcare providers to post at least one message on the social media platform of their choice using the hashtag #CrucialCOVIDConversations.

Sample social media posts:

- [Social Media Alert 1](#)
- [Social Media Alert 2](#)
- [Social Media Alert 3](#)



VA58 Trust & Safety Team Updates

The VA58 Trust & Safety Team reports on trending narratives about COVID-19, delivers biweekly briefings, and develops comprehensive resources to increase awareness around mis-, dis-, and mal-information, as well as the State's capacity to counter it.

BIWEEKLY BRIEFINGS

Biweekly briefings provide partners with the top COVID-19 vaccine mis/dis topics and trends, and invitees receive a copy of the report post-briefing.

To be added to the invite, email
rumors@cdph.ca.gov.


RUMORS INBOX

The Rumors Inbox serves as a tip line for our partners to submit the COVID-19 rumors they're hearing online and within their communities to our team. We incorporate the submissions into our team's reporting.



Report COVID-19 Vaccine Rumors to:

rumors@cdph.ca.gov



RECENT TOPICS & RESOURCES

Mis/Dis/Mal-information: Public health agencies & pharmaceutical companies are lying and withholding data about COVID-19 vaccine efficacy and safety.

Trusted Resources: [Developing COVID-19 Vaccines \(cdc.gov\)](#), [COVID-19 Vaccine Effectiveness | CDC](#)

Mis/Dis/Mal-information: Natural Immunity conferred by COVID-19 infection serves as a superior alternative to COVID-19 vaccines.


Trusted Resources: [Beneficios de vacunarse contra el COVID-19 | CDC](#), [Preguntas frecuentes sobre la vacunación contra el COVID-19 | CDC](#), VA58 Video with Mexican Consulate in Fresno: <https://fb.watch/bfN3zKrttE/>, [Post-COVID Conditions \(Long COVID\) \(ca.gov\)](#)

Stay informed!

Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

California COVID-19 Vaccination ProgramENHANCED BY Google

Program Updates

Program Enrollment

My Turn Onboarding

Vaccine Management

Vaccine Administration

Reporting Requirements

Archived Communications

Patient Resources

Provider Support

COVID Call Center

Email: [Program Info](#)
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

myCAvax and My Turn


Email:
[myCAvax Technical Support](#)
[MyTurn Onboarding](#),
[MyTurn Technical Support](#)
Phone: (833) 502-1245
Mon-Fri, 7AM-7PM
Sat-Sun, 8AM-1PM

My Turn Clinic Translation Line:
(833) 980-3933
Mon-Fri: 8AM-8PM
Sun-Sat: 8AM-5PM


Vaccines

[Manufacturer Contacts](#)


Updates for Providers




FAQ



Provider Office Hours



Training



Training Calendar

Alerts:

Updated Vaccination Schedule

- Interim Clinical Considerations: Intervals for mRNA Vaccine
- COVID-19 Vaccine Timing by Age (Eligibility Chart) | Spanish: Calendario de la Vacuna COVID-19 por Edad (Tabla de Elegibilidad)

Now Enrolling Providers of Pediatric Services

- Make NO Mistake-COVID-19 Is A Childhood Illness
- Benefits for Primary Care Providers
- Find Information on How to Enroll

Children 6 Months to 4 Years – ON HOLD as of 2/11/22

- Pfizer 6M-4Y No Longer Available for Pre-Orders
- Pfizer Training
- Comparison Guide of COVID-19 Vaccine Products


Featured Resources

Tools to Avoid Vaccine Mix-Ups:

- Comparison Guide of COVID-19 Vaccine Products
- COVID-19 Vaccine Timing by Age (Eligibility Chart)
- Vaccine Administration Checklist
- Preventing Administration Errors
- Coadministration of COVID-19 Vaccine with Other Vaccines | Tips | Preteens


Vaccine Management:

- Upcoming Expiration Dates
- Reporting Doses Spoiled, Expired, or Wasted (including Moderna booster doses)
- Ordering Vaccines | Ordering & Distribution Cadence
- Receiving Redistributed Small Orders
- Vaccine Management Checklist




COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 3/10/2022
- Currently in its 62nd iteration!

 **Q: Where can COVID-19 vaccine Providers find information on the Janssen (J&J) vaccine shelf-life extension?**

A: The Food & Drug Administration (FDA) extended the Janssen (J&J) vaccine shelf life from 6 months to 9 months. This shelf-life extension applies to all inventory dated to expire on March 7, 2022 or later. For further information, please visit [Janssen \(J&J\) COVID-19 Vaccine Expiration Extension](#).

 **Q: Is there a job aid that outlines COVID-19 vaccination interval timing by age?**

A: CDPH created a new job aid that outlines vaccine timing by age for both immunocompromised and immunocompetent individuals. Please view the COVID-19 Vaccine Timing by Age Chart in English [here](#) and in Spanish [here](#).

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

New and Updated FAQs.....	2
Pediatric Providers.....	2
Vaccine Program Management.....	3
Provider Enrollment.....	4
Ordering.....	4
Distribution/Redistribution.....	5
Vaccine Administration.....	5
Additional/Booster Doses.....	7
Vaccine Storage & Handling.....	9
Inventory.....	10
Reporting.....	11
Billing & Reimbursement.....	12
Communication Resources.....	12

[Provider FAQs on EZIZ, Updated Weekly](#)

COVID-19 Vaccination Program Webinars and Training for Providers

Week of March 14, 2022

Note: Calendar subject to change

	Monday 3/14	Tuesday 3/15	Wednesday 3/16	Thursday 3/17	Friday 3/18
myCAvax	Previewing Multi-Line Vaccine Ordering 10:00 am – 10:30 am				Provider Office Hours 9:00 am – 10:00 am
My Turn					
Combined Office Hours and Events	My Turn and myCAvax Office Hours 12 pm – 1 pm	Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: fVJzVYdN326	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: jEAtpMcM365	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: hwE2sdzwZ53	

* Pfizer BioNTech COVID-19 Vaccine Training & Education topics vary by day and include the latest information about vaccine storage, handling, preparation, and administration; recent medical updates, healthcare provider resources, and a Q&A session

View On Demand	<ul style="list-style-type: none">What's New in myCAvax for Release 21 (v. 1/18/22)Intro to My Turn Onboarding (v. 1/4/22)Latest Features in My Turn (* Requires My Turn Login)	<ul style="list-style-type: none">Provider 101 Account Enrollment: Section A: Organization Application (v. 10/21/21)Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21)Provider Office Hours and MCE Office Hours Archived Sessions	<ul style="list-style-type: none">Recording a Transfer/Redistribution Report (v. 12/20/21)Recording a Shipment Incident (v. 12/20/21)Using Multi-Line Ordering to Request Vaccine in myCAvax (v. 2/23/22)	<ul style="list-style-type: none">Recording an Excursion Event (v. 12/20/21)Recording a Waste Event (v. 12/20/21)
----------------	---	--	---	--

Help

Website: www.eziz.org/covid, [FAQs](#)
General email: covidcallcenter@cdph.ca.gov
CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov
myCAvax Help Desk Email: myCAvax.HD@accenture.com
Phone: (833) 502-1245


Vaccine Administration Data

Elizabeth Reosti, CDPH

Vaccine Administration Summary

as of March 10, 2022


Total Doses Administered: **72,069,472**




Trends in Vaccine Administration

as of March 7, 2022

New Doses Administered



New Doses Administered (thousands)




Booster* Vaccinations

as of March 7, 2022

Booster Rates by VEM/HPI Quartile


■ Q1 ■ Q2 ■ Q3 ■ Q4

-0%
23% gap in
booster
vaccinations
between Q1
and Q4



Booster Rates by Race/Ethnicity



-11%
below state
Average



5-to-11 Vaccinations

as of March 7, 2022

- Over the past 2 months, the gap in vaccination coverage between the most and least healthy places for children ages 12-to-17 has **decreased** by **2%** but **increased** for children ages 5-to-11 years by **5%**



COVID-19 Quality Assurance Site Visits

Steven Vantine and Kelsey Florio, CDPH

CDC Provider Participation Requirements

Providers are responsible for adhering to all requirements outlined in the agreement, including updated recommendations, requirements, and other guidance provided in the footnoted web links incorporated in the agreement.

Requirements for COVID-19 Vaccination Program Providers

All organizations and providers participating in the CDC COVID-19 Vaccination Program:

- **must** administer COVID-19 Vaccine at no out-of-pocket cost to the recipient
- may **not** deny anyone vaccination based on the vaccine recipient's coverage status or network status
- may **not** charge an office visit or other fee if COVID-19 vaccination is the sole medical service provided
- may **not** require additional medical services to receive COVID-19 vaccination
- **may** seek appropriate reimbursement from a program or plan that covers COVID-19 Vaccine administration fees for the vaccine recipient, such as:
 - vaccine recipient's private insurance company
 - Medicare or Medicaid reimbursement
 - HRSA COVID-19 Uninsured Program for non-insured vaccine recipients
- may **not** seek any reimbursement, including through balance billing, from the vaccine recipient

**COVID-19 Vaccine is
Provided at 100% No Cost
to Recipients**

Individuals aware of any potential violations of these requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services, by calling 1-800-HHS-TIPS or the website [TIPS.HHS.GOV](https://tips.hhs.gov)



[CDC COVID-19 Vaccine Provider Agreement](#)

[Requirements for COVID-19 Vaccination Providers](#)

[Data and Reporting](#)

[Additional Resources](#)



Reporting Requirements at a Glance

Reporting Requirements at a Glance



COVID-19 Vaccine

This guide outlines requirements in CDC's COVID-19 Vaccination Program Provider Agreement and [Vaccine Storage & Handling Toolkit](#). Refer to the EUA fact sheets or product inserts for vaccine-specific storage and handling and administration guidance. (See [Vaccine Administration](#) | [Vaccine Management](#) at a Glance.)

Topic	Requirements & Guidance	Resource
Reporting Doses Administered	<p><i>Within 24 hours of administering a dose of COVID-19 vaccine and adjuvant (if applicable), Organization must record in the vaccine recipient's record and report required information to the relevant state, local, or territorial public health authority. Details of required information (collectively, Vaccine Administration Data) for reporting can be found on CDC's website. (CDC Provider Agreement #2)</i></p> <p><i>Organization must submit Vaccine Administration Data through either (1) the immunization information system (IIS) of the state and local or territorial jurisdiction or (2) another system designated by CDC according to CDC documentation and data requirements. (P.A. #2)</i></p> <p>Providers must report vaccination data (including race and ethnicity) within 24 hours of administration and report doses administered daily to your local immunization registry. Providers may use My Turn, or an EHR/EMR connected to CAIR2, RIDE, or SDIR. (Providers already manually entering data into CAIR may continue to do so.)</p> <p>Report recipient's mobile number and email (see Health Officer Order).</p>	<p>Reporting Doses Administered</p> <p>Report Race & Ethnicity</p>
Reporting Administration Errors	<p><i>Organization must administer COVID-19 vaccine in accordance with all requirements and recommendations of CDC and CDC's Advisory Committee on Immunization Practices (ACIP). (CDC Provider Agreement #1)</i></p> <p>If an administration error occurs, refer to CDC's Interim Clinical Considerations (Appendix A) to identify any interim clinical recommendation and to locate these additional required actions listed below.</p> <ul style="list-style-type: none">• Inform the recipient of the vaccine administration error.	<ul style="list-style-type: none">• Reporting Administration Errors• Interim Clinical Considerations (Appendix A)

California COVID-19 Vaccination Program

IMM-1329 (3/8/22)

Share with staff that are responsible for oversight of the vaccination program within your practice.

Quality Assurance Site Visits

- **QA site visit goals:** Support providers to safely administer COVID-19 Vaccine!
 - Educational opportunities for you and staff to ensure compliance and vaccine safety
 - Highlight best practices/lessons learned
 - Share resources
- Resources available to you:
 - [Readiness Checklist for Covid Vaccine Program](#)
 - [Vaccine Timing by Age](#)
 - [Reporting Excursions](#)



CDC Requirements for Conducting Site Visits

- CDC requires states to conduct quality assurance site visits to COVID-19 Vaccination Program provider locations
 - Virtual site visits began June 2021
 - Currently virtual; In-person coming soon
 - Program requirement to allow site visits
- If your site is selected, you will receive communication from one of our reviewers at CDPH or an LHJ representative
 - LHJ's may be conducting visits in your county



Meet the QA Team

Colleen Mallen, MPH



Section
Chief of
Field
Services

Eugene
Beronilla, MPH



Covid-19
QA
Supervisor

Francisco Borboa, MPH



Covid-19
QA
Coordinator

Steven Vantine



Educational
Consultant

Meet the QA Team

Covid-19 Vaccine Nurse Consultants



Kelsey
Florio, RN



Kelley
Leung, RN,
BSN, PHN,
CEN, TNCC


Reviewers



Blanca Brosig, MPH



Christine Liu, MPH



Mayra Jacinto



Kasey Sumeriski



Sophia Artis



Pending

Quality Assurance Site Visits

Upcoming:

Where are common areas for support & improvement?

**Coming soon:
COVID QA-Dedicated Email for Questions**

Clinical Update

Caterina Liu, M.D., CDPH



Calendario de la Vacuna COVID-19 por Edad

1-page COVID-19 vaccine guidance schedule in Spanish

Guide breaks down the vaccination interval schedule by age and vaccine type

Calendario de la Vacuna COVID-19 por Edad

Edad	Vacuna	Calendario Rutinario
5-11	Pfizer-Pediatric (5-11)	
12+	Pfizer/Comirnaty (12+)	
18+	Moderna/Spikevax	
18+	Johnson & Johnson Pfizer/Moderna preferidos*	

Edad	Vacuna	Calendario si esta Moderadamente o Severamente Inmunocomprometido
5-11	Pfizer-Pediatric (5-11)	
12+	Pfizer (12+)	
18+	Moderna/Spikevax	
18+	Johnson & Johnson Moderna/Pfizer preferidos*	

^ Un [intervalo de 8 semanas](#) puede ser preferible para algunas personas, especialmente para hombres de 12 a 39 años.

* Aunque se prefiere el uso de vacunas ARNm COVID-19, la vacuna Janssen se puede ofrecer en [algunas situaciones](#). Consulte las [Consideraciones Clínicas Provisionales Para el uso de las Vacunas Contra el COVID-19 y Para Personas Inmunocomprometidas Moderado o Grave](#) para obtener más detalles. El calendario esta sujeto a cambios.

California COVID-19 Vaccination Program

IMM-1396 (3/4/22)

COVID-19 Vaccine Timing by Age

Age	Vaccine	Routine Schedule
5-11	Pfizer-Pediatric (5-11)	1st Dose → 3 weeks → 2nd Dose
12+	Pfizer/Comirnaty (12+)	1st Dose → 3-8 weeks* → 2nd Dose → ≥5 months → Booster 12-17: Pfizer 18+: Pfizer/Moderna (preferred) or J&J*
18+	Moderna/Spikevax	1st Dose → 4-8 weeks* → 2nd Dose → ≥5 months → Booster of Moderna/Pfizer (preferred) or J&J*
18+	Johnson & Johnson Pfizer/Moderna preferred*	1st Dose → ≥2 months → Booster of Moderna/Pfizer (preferred) or J&J*

Age	Vaccine	Schedule if Moderately or Severely Immunocompromised
5-11	Pfizer-Pediatric (5-11)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose
12+	Pfizer (12+)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥3 months → Booster 12-17: Pfizer 18+: Pfizer/Moderna (preferred) or J&J*
18+	Moderna/Spikevax	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥3 months → Booster of Moderna/Pfizer (preferred) or J&J*
18+	Johnson & Johnson Moderna/Pfizer preferred*	1st Dose → 4 weeks → 2nd Dose of Pfizer or Moderna → ≥2 months → Booster of Moderna/Pfizer (preferred) or J&J*

^ An 8-week interval may be preferable for some people, especially for males 12-39 years.

* Although use of mRNA COVID-19 vaccines is preferred, the Janssen vaccine may be offered in some situations.


View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) and [COVID-19 Vaccines for Moderately or Severely Immunocompromised People](#) for details. Schedule is subject to change.

California COVID-19 Vaccination Program

IMM-1396 (2/25/22)

UK: Pfizer Vaccine Effectiveness (VE) vs Omicron Symptomatic Infection in Adults


B Two Doses of BNT162b2 with a Booster Dose of BNT162b2 or mRNA-1273



- UK study in adults 18+
- VE lower for Omicron compared to Delta
- VE against infection wanes substantially after primary series
- VE against infection improves with a booster.


UK: Moderna VE vs Omicron Symptomatic Infection in Adults

C Two Doses of mRNA-173 with a Booster Dose of BNT162b2 or mRNA-1273



- Similar pattern for Pfizer and Moderna vaccines
- VE lower for Omicron compared to Delta
- VE against infection wanes substantially after primary series
- VE against infection improves with a booster.

UK: Pfizer VE vs Omicron Hospitalization in Adults



- UK study in adults 18+
- VE vs hospitalization lower for Omicron compared to Delta
- VE vs hospitalization wanes after Pfizer primary series
- VE against hospitalization improves with a booster.

US: Pfizer VE vs Omicron ED visits in Children

Encounter type/Vaccination status	Total	SARS-CoV-2 test-positive, no. (%)	VE %* (95% CI)
ED or UC encounters, by age group and predominant variant			
5–11 yrs**			
Omicron predominant^{††}			
Unvaccinated (Ref)	5,938	2,409 (40.6)	—
2 doses (14–67 days earlier)	486	118 (24.3)	51 (30–65)
12–15 yrs			
Omicron predominant^{††}			
Unvaccinated (Ref)	2,336	1,254 (53.7)	—
2 doses (14–149 days earlier)	472	174 (36.9)	45 (30–57)
2 doses (≥150 days earlier)	719	346 (48.1)	–2 (–25–17)
3 doses (≥7 days earlier)	10	3 (30.0)	NC
16–17 yrs			
Omicron predominant^{††}			
Unvaccinated (Ref)	1,363	771 (56.6)	—
2 doses (14–149 days earlier)	263	114 (43.4)	34 (8–53)
2 doses (≥150 days earlier)	565	282 (49.9)	–3 (–30–18)
3 doses (≥7 days earlier)	62	13 (21.0)	81 (59–91)

- VE against Emergency Department (ED) or Urgent Care (UC) visits
- VE higher vs ED/UC visits for Delta vs Omicron
- In children 12+, VE vs ED/UC encounters waned substantially after the primary series, similar to findings in adults
- In children 16-to-17, a booster dose improved protection vs ED/UC encounters
- In children 5-to-11, VE within 2 months of primary series was 51%, similar to estimates in adults


US: Pfizer VE vs Hospitalization in Children

Encounter type/Vaccination status	Total	SARS-CoV-2 test-positive, no. (%)	VE %* (95% CI)
Hospitalizations during Delta or Omicron predominance, by age group			
5–11 yrs			
Unvaccinated (Ref)	262	59 (22.5)	—
2 doses (14–67 days earlier)	23	2 (8.7)	74 (–35–95)
12–15 yrs			
Unvaccinated (Ref)	496	149 (30)	—
2 doses (14–149 days earlier)	182	7 (3.8)	92 (79–97)
2 doses (≥150 days earlier)	63	13 (20.6)	73 (43–88)
16–17 yrs			
Unvaccinated (Ref)	437	136 (31.1)	—
2 doses (14–149 days earlier)	150	7 (4.7)	94 (87–97)
2 doses (≥150 days earlier)	82	14 (17.1)	88 (72–95)
3 doses (≥7 days earlier)	4	1 (25.0)	NC

- VE against hospitalization after 2 doses of vaccine remains high in all age groups during Delta and Omicron
- 5-to-11-year-old data limited by small numbers and large confidence interval

NY: Pfizer VE vs Any Omicron Infection in Children

Figure 1: Vaccine Effectiveness against Infection, by Week and Year of Age



- Primary series VE against any Omicron infection (defined as positive PCR or antigen test)
- VE vs. infection estimates similar to findings in adults
- VE vs infection during Omicron surge in Jan 2022 waned rapidly for children 5-to-11 years
- VE vs infection remained sustained for children 12-to-17 during the same time period

Figure 2: Incidence rate ratios, comparing cases during January 3 - January 30, 2022 for unvaccinated versus children newly fully-vaccinated December 13, 2021-January 2, 2022, by Time Since Full Vaccination

NY: Pfizer VE vs Hospitalization in Children

Table 1: New COVID-19 Cases and Hospitalizations by Vaccine Status, Children Ages 5-17 in New York State, November 29, 2021 – January 30, 2022

Week	Events		Rates per 100k		Incidence Rate Ratios, Vaccine Effectiveness				Full-vaccine Coverage
	Vacci-nated	Unvacci-nated	Vacci-nated	Unvacci-nated	IRR	(95% CI)	VE	(95% CI)	%
5-11 years^a									
Dec. 13-19	0	18	0.00	0.22	+inf.	(0.3, +inf.)	100%	(-189, 100%)	4.7%
Dec. 20-26	2	50	0.17	0.63	3.6	(1.0, 30.9)	73%	(-7, 97%)	10.6%
Dec. 27-Jan. 2	3	80	0.19	1.04	5.5	(1.8, 27.1)	82%	(45, 96%)	14.5%
Jan. 3-9	5	78	0.28	1.04	3.8	(1.6, 12.0)	74%	(36, 96%)	16.6%
Jan. 10-16	6	68	0.29	0.94	3.2	(1.4, 8.9)	68%	(28, 91%)	18.6%
Jan. 17-23	8	46	0.35	0.65	1.9	(0.9, 4.6)	46%	(-15, 77%)	21.0%
Jan. 24-30	8	42	0.31	0.60	1.9	(0.9, 4.8)	48%	(-12, 75%)	23.4%
12-17 years									
Nov. 29-Dec. 5	2	20	0.04	0.61	16.9	(4.1, 148.8)	94%	(76, 99%)	58.4%
Dec. 6-12	1	11	0.02	0.34	19.0	(2.8, 818.3)	95%	(64, 100%)	58.8%
Dec. 13-19	6	23	0.11	0.72	6.8	(2.7, 20.4)	85%	(63, 95%)	59.3%
Dec. 20-26	18	45	0.31	1.44	4.6	(2.6, 8.4)	78%	(63, 88%)	59.9%
Dec. 27-Jan. 2	38	77	0.66	2.50	3.8	(2.5, 5.8)	74%	(61, 84%)	60.4%
Jan. 3-9	47	94	0.81	3.10	3.8	(2.7, 5.6)	74%	(63, 82%)	60.9%
Jan. 10-16	41	85	0.70	2.84	4.1	(2.8, 6.0)	75%	(64, 86%)	61.3%
Jan. 17-23	34	67	0.58	2.26	3.9	(2.6, 6.1)	75%	(61, 83%)	61.9%
Jan. 24-30	22	40	0.37	1.36	3.7	(2.1, 6.5)	73%	(53, 87%)	62.4%

^a <1% of this age group fully vaccinated in previous weeks


- Note: Omicron was >90% of cases starting January 2022
- High VE vs Omicron hospitalization after primary series in children 5-to-11 and 12-to-17
- Hospitalization remains uncommon among children

Summary: COVID-19 Vaccine Effectiveness in Children and Adults

- COVID-19 vaccines remain highly protective at all ages against severe COVID-19 caused by Omicron.
- Immunization is less protective against milder Omicron infection, and protection against infection may be briefer for children 5-to-11.
- More data on vaccine effectiveness in pediatric populations is expected to follow over the coming weeks to months.
- There are no changes to recommendations or operations, currently.


Booster Vaccines are Safe Among Persons Aged 12-to-17 years

- Updated review of national COVID-19 vaccine safety data
- Reactions after booster vaccination were mild to moderate and transient
- The frequency of reported local and systemic reactions were similar after the booster dose and second dose.
- Myocarditis was less frequently reported after a booster dose than after a second dose.



Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Storage & Handling

Kate McHugh, CDPH

Janssen Shelf-Life Extension

- Shelf life extended from 6 months to 9 months
- Decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 9 months when refrigerated at temperatures of 2° – 8° Celsius.
- Applies to ***inventory dated to expire on March 7, 2022, or later***
- Vaccine providers should visit the [Janssen COVID-19 Vaccine Expiry Checker](#) webpage to confirm the expiration dates.
- [Expiration Extension Communication from Call Center](#)

Expiration Dates

- [Janssen COVID-19 vaccine by Johnson & Johnson expiry checker](#)
- [Moderna COVID-19 vaccine expiry checker](#)
- [Pfizer COVID-19 adult \(12+ years, purple cap\(must dilute\) expiry extension](#) (page 4)
- [Pfizer COVID-19 pediatric \(5-11 years, orange cap\) vaccine expiry extension](#) (page 4)
- [Pfizer COVID-19 adult \(12+ years, gray cap\) vaccine expiry extension](#) (page 5)

Temperature Excursions

- Janssen: [Stability Information \(janssenmd.com\)](https://www.janssenmd.com)
- Moderna: [Storage & temperature excursion for Moderna COVID-19 vaccine \(modernamedinfo.com\)](https://www.modernamedinfo.com)
- Pfizer
 - Pfizer 1170 (12+ years, **purple cap**): [medical information](#)
 - Pfizer Tris-sucrose (12+ years, **gray cap**): [medical information](#)
 - Pfizer pediatric (5-11 years, **orange cap**): [medical information](#)
 - Pfizer Digital Assistant: [Search Medical Information | Pfizer Medical Information - US](#)
 - This information can help you find quick answers to temperature excursions.
 - If you have difficulty interpreting, you can contact CDPH or Pfizer.
- Even if the vaccine is viable, still report the excursion in myCAvax!

AmerisourceBergen (Third Party Redistributor) Shipment Incidents

What do you do if you receive a shipment that has a temperature excursion?

- Report as a shipping incident in myCAvax
- Contact AmerisourceBergen (AB) at: c19vaccineops@amerisourcebergen.com
 - Include the downloaded temperature log, your order number, and your shipment incident number in your email
- AmerisourceBergen will contact Pfizer and determine if the vaccine is viable. The provider does not need to contact Pfizer!
- If you have any issues receiving a reply from AmerisourceBergen, reach out to the COVID Call Center: covidcallcenter@cdph.ca.gov to let us know.
- Job aid: [IMM-1387.pdf \(eziz.org\)](https://www.eziz.org/IMM-1387.pdf)



Pfizer COVID-19 Vaccine Medical Updates & Training Sessions

Date & Time (linked)	Password
Tuesday, March 15 – 12PM	fVJzVYdN326
Wednesday, March 16 – 9AM	jEAtpMcM365
Thursday, March 17 - 9AM	hwE2sdzwZ53
Tuesday, March 22 - 12PM	miSmuZnQ358
Wednesday, March 23 - 9AM	iPdKJ8Cia66
Thursday, March 24 - 9AM	xpM3jXQu7K5
More sessions listed! NOTE: All times listed here are P.S.T.	

For providers and immunization staff personnel. **Please attend one of these sessions!**

Topics include:

- Introduction of new Controlant Temperature Monitoring Device
- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
 - Ages 5 through 11 Years
 - Ages 12 Years and Older

Vaccine Management

Eric Norton and Claudia Aguiluz, CDPH

Release 24: Joint Clinic Set-Up for COVID-19 and Flu

Clinic Setup 0% Complete

STEP 1
Set up your clinic

Clinic name and location
We recommend keeping your clinic's public-facing name (what appears on My Turn) to Site name-location. To differentiate clinics internally, add more detail to the internal clinic name, such as vaccine type, brand, or dose.

* Internal Clinic Name ⁱ

* Public Clinic Name ⁱ

Clinic Description ⁱ

Location Map URL

By inputting a google map link, your clinic will appear on the public portal's "View Map" link.

Provide the address where your clinic will be administering vaccines.

Address

Street

City State/Province

Zip/Postal Code Country

Healthcare provider location
Your clinic must be associated with a healthcare provider location enrolled in the myCAVax COVID-19 Vaccination Program. If you are unsure which location your clinic is associated with, please contact your organization's liaison or Production Support at 1-833-422-4255 or myturn.clinic.hd@accenture.com.

* Provider Location

Search Accounts...

Vaccine Type
Please specify what type and brand of vaccine your clinic will offer. These values can be updated later in your clinic's vaccine inventory tab.

* Vaccine Type


☒ COVID-19

☐ Flu

During Clinic Set-Up, there is now the option to **select both COVID-19 and Flu for the Vaccine Type** and the product options will all be available for selection.



Release 24: Help Desk Chat Updates



The Help Desk Chat Icon is available on the unauthenticated Login page for both My Turn and myCAVax.



Additionally, you can **upload attachments** when using the Help Desk Chat feature.

Release 24: Bulk Inline Edit/Upload Feature


The screenshots illustrate the bulk upload process in the myCAVax system. The first screenshot shows the 'Bulk upload appointments' page with the 'Inline bulk upload' button highlighted. The second screenshot shows the 'Bulk upload appointments' page with the 'Error file' link highlighted. The third screenshot shows the 'Error report' modal with the 'Submit' button highlighted.

This new inline feature will make Bulk Uploads *so easy!*

1. Use the **Inline Bulk Upload** feature to add appointments directly in My Turn.
2. After processing the upload, you can access **links to reports regarding the success of the upload** and outlining any errors.
3. You can review the error report and **make updates directly to any uploaded field that's associated with an error**. Once you submit the error report, the upload should be processed.

My Turn Mary - Bulk Inline Upload Feature

A few patients need to have their appointments recorded in My Turn. I want to try the new inline Bulk Upload feature to complete this right in My Turn!



The screenshot shows the myCAVox Bulk upload appointments page. At the top, there are navigation links for Home, Bulk upload walk-ins, and Add Walk-in Appointment. Below this, the page title is "Bulk upload appointments" with a sub-note: "Choose from one of the upload options below to get started. You are only able to use one option (inline or CSV) at a time." There are two main options: "Inline bulk upload" (selected) and "CSV bulk upload". Under "Inline bulk upload", there is a section titled "Use the table below to quickly add up to 10 appointments at a clinic." with a "Clinic Name" dropdown and "Clear form" and "Upload appointments" buttons. Below this is a table with columns: First name, Last name, Email, Mobile, Date of birth, Gender, Hispanic/Latino or Spanish origin, Ethnicity, Race, Marital status, Client ID, Street address, City, State, and Zip code. The table has two rows of input fields. At the bottom, there is an "Add new" button and a progress bar.


Update up to 10 patients at a time using the Inline Bulk Upload. This feature is so easy to use and requires the same information required in the CSV file.

I'm so glad this feature is now available!


Release 23 Update

We are planning a big release that will incorporate all scheduled updates from February 24th and March 17th. This will go live on **March 17th**.


We are also incorporating feedback for the Multi-line Ordering feature such as:



Removing the
Intended Use
question.



Adding an Ancillary Kit
Opt-out tool tip and
message that lets
Providers know whether
they can Opt-out for
certain Products.



Updating the Order
Increments column to
clarify what the minimum
for that Product is and how
it should increment based
on the Order size

Janssen Reminders



Providers – **please place Small Orders for Janssen when possible!**
Ensure your orders follow current guidance for use and ordering.



LHDs/MCEs--When ordering J&J, email the COVID-19 Provider Call Center at covidcallcenter@cdph.ca.gov with rationale of need received from providers. We are aware specific populations are requesting this product and will do our best to support where we can.



Work with your LHJs when placing these orders!

APPENDIX

What's Next on My Turn: Release 24 (03/09)

My Turn Public

General Enhancements

- ✓ Age range question was updated with the date of birth on Let's Get Started page for COVID individual and Flu flow.
- ✓ Third-party clinics are filtered based on Vaccine Supply
- ✓ 8-week interval between 1st and 2nd dose for Pfizer and Moderna initial series is allowed.
- ✓ Security update was processed.
- ✓ Date of Birth validation was updated for the homebound flow so that the patient is at least 5 years old.
- ✓ Minors can get Pfizer booster only on Moderna or J&J flow.

My Turn Clinic

General Enhancements

- ✓ Clinic Managers can create a clinic for both Flu and COVID.
- ✓ Auto-populate COVID-19 calendar date based on eligibility when processing a walk-in appointment.
- ✓ Geofencing Tooltip language was updated.
- ✓ Live Chat was added to myCAvax & My Turn Portal login, and you can attach Files through Live Chat.
- ✓ Pediatric Filter was added on the Appointments tab.
- ✓ Resource link was added for the accordion flu flow.
- ✓ Inline Bulk Editing Functionality was added.
- ✓ J&J eligibility expansion was assessed and solutioned.
- ✓ You can right click to open Record Detail page in new window.

myCAvax – Known Issues - *Updated 3/3*



Known Issues

Not all Users are Assigned “Calvax Partner Community User”

- ✓ We are investigating an issue where some users are not being automatically assigned to the correct profile when their first Location Application is approved.

Shipping Hour Four-Hour Window Requirement Bypass

- ✓ We are working on fixing an issue where users who do not add a four-hour window in their shipping hours are not shown an error immediately and are allowed to continue with their Section B enrollment up until it's time to submit DocuSign.



Workaround/Next Steps

- ✓ Fix: TBD
 - ✓ Please contact the Provider Call Center, if you are unable to see 'Vaccine Orders' and 'Vaccine Inventory' tabs in your Community portal after your Location Application has been approved
-
- ✓ Fix: 3/17/2022
 - ✓ No Workaround. Please enroll new locations with at least one four-hour window.

Wrap-up

Leslie Amani, CDPH

Additional Support

Type of Support

Description

Updated 12.29.21



COVID-19 Provider Call Center

The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: covidcallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–6PM



Enrollment Support

For Provider enrollment support, please contact myCAvax Clinic Operations at

- Email: myCAvaxinfo@cdph.ca.gov



myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: myCAvax.HD@Accenture.com
- Phone: (833)-502-1245, option 3, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM-1PM

For training opportunities: <https://eziz.org/covid/education/>



My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): myturnonboarding@cdph.ca.gov

For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Accenture.com or (833) 502-1245, option 4: Monday through Friday 7AM–7PM, Saturday and Sunday 8AM–1PM.

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)

Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



Monitor What You See and Hear

Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, **report** it to **rumors@cdph.ca.gov**

[Contact](#)

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Thank you!



Monday:

My Turn myCAvax

Zoom Link

Next session: Monday, March 14 at 12:00 PM

Friday:

Provider Office Hours

Zoom Link

Next session: Friday, March 18 at 9:00 AM

Thank you to Provider Office Hours' Planning Team: Leslie Amani, Rachel Jacobs, Hailey Ahmed, Blanca Corona, and Reva Anderson.